HIV/AIDS denialism

AHF Backs Congressional Push to Protect HIV/AIDS Funding

Retrieved on: 
Monday, February 26, 2024

It would be penny wise and pound foolish to undo the amazing progress that has been made in combatting HIV in America,” said Michael Weinstein, AHF president and cofounder.

Key Points: 
  • It would be penny wise and pound foolish to undo the amazing progress that has been made in combatting HIV in America,” said Michael Weinstein, AHF president and cofounder.
  • “Republicans should remember that it was former President Trump who inaugurated the Ending the HIV Epidemic in the U.S. program.
  • To learn more about AHF, visit us online at AIDShealth.org , find us on Facebook , follow us on Instagram , Twitter , and TikTok , and subscribe to our AHFter Hours podcast.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20240223537702/en/

Gilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDS

Retrieved on: 
Tuesday, October 24, 2023

Gilead Sciences, Inc. (Nasdaq: GILD) today was recognized as the number one philanthropic funder of HIV-related programs for the second year in a row, in a new report released by Funders Concerned About AIDS (FCAA).

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) today was recognized as the number one philanthropic funder of HIV-related programs for the second year in a row, in a new report released by Funders Concerned About AIDS (FCAA).
  • “We know that progress against HIV depends on more than scientific innovation, which is why we support the community organizations doing remarkable work to eliminate barriers to care.
  • “This support is more essential than ever given the incredibly challenging environment in which we find ourselves.
  • Initiative – a 3-year, $10 million commitment to increase HIV prevention, anti-stigma and health equity efforts for Black cisgender and Transgender women and girls in the United States.

Gilead Showcases Latest HIV Pipeline Progress and the Impact of Global Collaboration on Health Equity Efforts at IAS 2023

Retrieved on: 
Wednesday, July 19, 2023

As the leader in HIV innovation, Gilead will provide updates on its signature initiatives and key collaborations while sharing new scientific data from its research and development programs.

Key Points: 
  • As the leader in HIV innovation, Gilead will provide updates on its signature initiatives and key collaborations while sharing new scientific data from its research and development programs.
  • Gilead is committed to continuous scientific discovery to meet the evolving needs of people affected by HIV.
  • At IAS 2023, Gilead will share new findings on HIV treatment and prevention strategies, as well as the latest updates from the company’s continued pursuit of an HIV cure.
  • Gilead scientists will also contribute to three IAS-hosted satellite sessions to further advance scientific dialogue on key issues including:

Collaborative Research Promotes Thomas Rodriguez-Schucker to President

Retrieved on: 
Wednesday, March 1, 2023

AUSTIN, Texas, March 1, 2023 /PRNewswire/ -- Collaborative Research, a strategic planning health care firm supporting local public health, social-service and community-based organizations for the past 20 years, today announced the appointment of Thomas Rodriguez-Schucker to President. The news comes as Founder and CEO Jeff Daniel steps away to focus on the launch of the Collaborative Research Foundation, a new 501c3 non-profit that will roll out in Q4 of 2023.

Key Points: 
  • AUSTIN, Texas, March 1, 2023 /PRNewswire/ -- Collaborative Research , a strategic planning health care firm supporting local public health, social-service and community-based organizations for the past 20 years, today announced the appointment of Thomas Rodriguez-Schucker to President.
  • The news comes as Founder and CEO Jeff Daniel steps away to focus on the launch of the Collaborative Research Foundation, a new 501c3 non-profit that will roll out in Q4 of 2023.
  • "As we continue the hard work of bringing an End to the HIV Epidemic, there is no better leader than Thomas to drive Collaborative Research's continued focus on that mission.
  • "It's all the more exciting as Jeff moves forward with the Collaborative Research Foundation, which will raise the bar for delivering exceptional prevention and care on a national level and will further our collective mission to End the HIV Epidemic."

Huichao Liang, An Expert on AIDS Combined with Gynecological Oncology, Receives Excellent Popular Science Worker Award

Retrieved on: 
Friday, February 24, 2023

Among gynecological tumors, cervical cancer, endometrial cancer and ovarian cancer are still the most important female reproductive system malignancies threatening women's health.

Key Points: 
  • Among gynecological tumors, cervical cancer, endometrial cancer and ovarian cancer are still the most important female reproductive system malignancies threatening women's health.
  • How to improve the survival rate and cure rate of gynecological tumor patients is the focus of research of gynecological oncology experts at home and abroad.
  • Huichao Liang spent a lot of time and energy on the integration and improvement of the medical team.
  • As an infectious disease combined with gynecological oncology expert, Huichao Liang must face the terrible viruses and bacteria and defeat them with wisdom.

OraSure Wins Contract to Supply “Together Take Me Home,” HIV Self-Testing Initiative Sponsored by the Centers for Disease Control and Prevention

Retrieved on: 
Tuesday, September 20, 2022

This program follows a successful collaborative pilot program by the same name, for which OraSure also supplied tests.

Key Points: 
  • This program follows a successful collaborative pilot program by the same name, for which OraSure also supplied tests.
  • As part of the program, OraSure will provide up to one million OraQuick In-Home HIV tests over a five- year period.
  • The program will target populations that are disproportionately affected by HIV and less likely to have access to key prevention services.
  • The OraQuick In-Home HIV Test is the first and only oral fluid rapid over-the-counter (OTC) HIV test approved in the U.S.

AHF Targets Gilead on Drug Pricing @ Baird Global Healthcare Conference

Retrieved on: 
Tuesday, September 13, 2022

(Graphic: Business Wire)

Key Points: 
  • (Graphic: Business Wire)
    Gilead officials will be presenting at the conference and the advocates will protest GileadGreediadover the drug companys latest, and illegal move to undermine safety net providers access to 340B program benefits.
  • AIDS Drug Pricing PROTEST targeting Gilead Sciences, Inc.
    111 E. 48th Street (between Park & Lexington Aves.
  • ), New York, NY 10017
    In March of this year, Gilead became the 15th drug manufacturer to place unlawful restrictions on 340B contract pharmacy programs.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth , follow us @aidshealthcare or subscribe to our AHF podcast AHFter Hours.

AHF Protests Gilead over Drug Pricing @ Morgan Stanley Conference

Retrieved on: 
Tuesday, September 13, 2022

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220912005989/en/
    AHF has been targeting Gilead Sciences, Inc. as "Greediad" over the drug company's AIDS drug pricing and policies as well as illegal restrictions Gilead is placing on access to its lifesaving drugs through the 340B program.
  • Gilead officials will be presenting at the conference and the advocates will protest Gilead as Greediad over the drug companys latest, and illegal move to undermine safety net providers access to 340B program benefits.
  • AIDS Drug Pricing PROTEST targeting Gilead Sciences, Inc.
  • In March of this year, Gilead became the 15th drug manufacturer to place unlawful restrictions on 340B contract pharmacy programs.

HOW HAVING FEARLESS CONVERSATIONS CAN HELP YOU THRIVE WHILE LIVING WITH HIV

Retrieved on: 
Wednesday, September 7, 2022

TITUSVILLE, N.J., Sept. 7, 2022 /PRNewswire/ --

Key Points: 
  • Today, living with HIV means you can still thrive with HIV, which means prioritizing your health and wellbeing.
  • It calls for self-reflection, requires self-acceptance and demands a daily commitment to living our best lives.
  • Self-care might look different for everyone, but at its core, it's about putting your health and wellness first.
  • 1"Global Statistics: The Global HIV And AIDS Epidemic, The U.S. Department of Health and Human Services, Accessed August 5, 2022. https://www.hiv.gov/hiv-basics/overview/data-and-trends/global-statistics

Gilead Sciences Announces Collaboration With Morehouse School of Medicine and Xavier University of Louisiana College of Pharmacy to Address Inequities in HIV Care

Retrieved on: 
Wednesday, August 17, 2022

The collaboration is focused on addressing the inequities in HIV care for Black communities in the Southern United States.

Key Points: 
  • The collaboration is focused on addressing the inequities in HIV care for Black communities in the Southern United States.
  • View the full release here: https://www.businesswire.com/news/home/20220816005886/en/
    Research shows that inequities drive higher rates of HIV infection, as well as worse HIV clinical outcomes among Black Americans.
  • The Satcher Health Leadership Institute will collaborate with Gilead and Xavier University of Louisiana to ensure these communities are not an afterthought.
  • For more information about Gilead, please visit the companys website at www.gilead.com , follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.